10-Q: NanoViricides Advances Antiviral Pipeline, Secures $6M Funding

NanoViricides reports reduced quarterly net loss and significant progress in its broad-spectrum antiviral drug NV-387, including Phase II approval for MPox, while addressing going concern doubts with recent capital raises.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $1.79 million, down from $3.13 million in the prior year period.
• Research and development expenses decreased by $940,025 to $993,066, primarily due to lower outside lab fees.
• General and administrative expenses decreased by $431,124 to $803,619, mainly due to reduced professional fees for investor outreach.
• Cash and cash equivalents stood at $1.13 million as of September 30, 2025.
• The company raised approximately $6 million in gross proceeds through a registered direct offering and ATM sales between October 1 and November 12, 2025.
• NV-387, the lead drug candidate, successfully completed a Phase I human clinical trial for safety and tolerability with no reported adverse events.
• Final approval was received for a Phase II clinical trial of NV-387 for MPox treatment in the Democratic Republic of Congo (DRC) at the end of October 2025.
• The company is planning a Phase II clinical trial for NV-387 as an empiric therapy for viral Acute and Severe-Acute Respiratory Infections (V-ARI and V-SARI) in India.
• Efforts to find COVID-19 patients for the Phase 1a/1b clinical trial were unsuccessful, leading to its closure in April 2024 for the COVID-19 indication.
• The company continues to seek non-dilutive funding and partnerships for NV-387 development for COVID and Long COVID indications.
• Dr. Anil Diwan's and Meeta Vyas's employment agreements were extended for one year, through June 30, 2026.
• The company's line of credit with Dr. Anil Diwan was increased to $3 million and extended to March 31, 2027, with no drawdowns as of September 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company faces significant financial challenges, including a going concern warning and accumulated deficit, the substantial progress in clinical trials for NV-387 (Phase I completion, Phase II approval for MPox) and successful capital raises post-period are strong positive indicators for future development and potential value creation. The reduction in net loss and operating expenses also contributes positively, despite the lack of revenue.

Positives

• Net loss significantly decreased to $1.79 million from $3.13 million year-over-year, indicating improved cost management.
• Research and development expenses decreased by 48.6% to $993,066, reflecting efficiencies or completion of certain costly studies.
• General and administrative expenses decreased by 34.9% to $803,619, showing reduced overheads.
• NV-387 successfully completed its Phase I human clinical trial with no reported adverse events, validating its safety and tolerability.
• Final approval for a Phase II clinical trial of NV-387 for MPox in DRC is a significant regulatory milestone.
• NV-387 demonstrated strong activity in lethal animal models against Coronaviruses, RSV, Smallpox/MPox, Influenza, and Measles, suggesting broad-spectrum potential.
• The company's in-house cGMP-compliant manufacturing facility allows for cost savings and rapid production of drug candidates.
• Recent capital raises of approximately $6 million post-period provide crucial funding for ongoing operations and clinical trials.
• The company is pursuing Orphan Drug Designations (ODD) for NV-387 for MPox, Smallpox, and Measles, which could accelerate regulatory paths and provide economic benefits like tax breaks and market exclusivity.
• The unique host-mimicry platform technology of nanoviricides is designed to prevent viral escape through mutations, a significant advantage over traditional antivirals and vaccines.

Negatives

• The company has an accumulated deficit of approximately $150.6 million and has not generated any revenues, with none anticipated in the foreseeable future.
• A 'substantial doubt' exists about the company's ability to continue as a going concern, as current and recently raised capital are not sufficient for 12 months of planned operations.
• Cash and cash equivalents decreased to $1.13 million at September 30, 2025, from $1.56 million at June 30, 2025.
• The Phase 1a/1b clinical trial for COVID-19 was closed due to the inability to find eligible PCR-positive COVID patients, preventing efficacy data collection for this indication.
• Interest income decreased significantly to $11,627 from $41,023, reflecting lower cash balances and interest rates.
• The company is highly dependent on license agreements with TheraCour Pharma, Inc., a related party, for its proprietary information and technology.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing losses and insufficient capital to fund operations for at least 12 months from the filing date.
• The company has not generated any revenues and no revenues are anticipated in the foreseeable future, requiring continuous external financing.
• There is no assurance that the company will achieve or maintain profitability in the future.
• The ability to continue as a going concern is dependent upon controlling overall expenses and securing additional financing, which may not be successful on acceptable terms.
• The company's plans are subject to change, and changed circumstances could deplete capital resources more rapidly than anticipated.
• There is no assurance that the company will be successful in obtaining sufficient financing on acceptable terms to fund continuing operations.
• The company has limited experience with pharmaceutical drug development, and budget estimates are not based on extensive experience, potentially leading to inaccuracies or cost overruns.
• Dependence on external collaborators, service providers, and consultants for drug development work introduces risks related to their performance and cost estimates.
• The FDA or other international regulatory agencies may require additional studies or have different requirements, leading to delays or increased costs for drug approval.
• There is no guarantee of success in partnering drug candidates or obtaining non-dilutive funding for drug development programs.
• Manufacturing nanomedicines under cGMP conditions has been identified as a major risk in the industry, potentially leading to program failures.

Future Outlook

The company anticipates several key milestones, including finalizing the Phase Ia/Ib clinical study report for NV-387, submitting it to Indian regulatory authorities, and filing a Clinical Trial Application (CTA) for a Phase II clinical trial of NV-387 for MPox. They also plan to apply for Orphan Drug Designations (ODD) from the US FDA for NV-387 for MPox, Smallpox, and Measles, which could accelerate regulatory timelines and provide economic benefits. Further plans include Pre-IND applications with the US FDA and leveraging successful MPox Phase II data for a potential Phase II/III licensure trial. The company is also planning a novel Phase II clinical trial in India for NV-387 as an empiric therapy for various respiratory viral infections (Influenza, COVID, RSV, hMPV). Management believes achieving these milestones will improve stock liquidity and enhance future fundraising capabilities, while actively exploring non-dilutive grants, contracts, partnering, and debt or equity financing.

Management Comments

• Management believes that the company's cash and cash equivalents balance along with additional capital raised and the line of credit will not be sufficient to fund planned operations for at least 12 months from the filing date, indicating substantial doubt about going concern.
• Management believes that as various milestones are achieved, the company would likely experience improvement in the liquidity of the company's stock, enhancing its ability to raise funds on favorable terms.
• Management believes that it has on-going access to the capital markets including the At-The-Market (ATM) agreement with D. Boral Capital.
• We believe the report should be finalized soon regarding the Phase Ia/Ib clinical study report (CSR) for NV-387.
• We believe that the MPox Phase II if successful, will likely enable a Phase II/III licensure clinical trial under the US FDA auspices upon completion, which may provide the shortest possible timeline for NV-387 licensure.
• We believe that the ODDs will provide several benefits that would accelerate the NV-387 program towards regulatory licensure.
• We believe that the planned Phase II Viral ARI/SARI Clinical Trial will provide us with substantial actionable data on the safety and effectiveness of NV-387 in treating at least Influenza, RSV, COVID, and provide further information in the utility of NV-387 against many other respiratory viruses.
• We believe NV-387 could revolutionize the treatment of viral infections the same way that penicillin revolutionized the treatment of bacterial infections.
• We therefore anticipate that NV-387 can be given to patients across all patient population, in age from infants to seniors, including immunocompromised persons, patients with co-morbidities, and others, when approved.
• We believe NV-387 can meet the challenge of becoming an effective treatment for MPox infection that is currently ravaging in multiple nations in Central Africa.
• We believe this could be as revolutionary for the treatment of viral infections as the discovery of penicillin was for the treatment of bacterial infections.
• We believe NV-387 is such a drug that could be deployed both as a treatment and as a prophylactic for Measles, thereby taking away the social and educational disruption that Measles causes.
• We believe NV-387 would be effective against H5N1 bird flu as well. Also we believe NV-387 would be effective against influenza viruses resistant to available drugs.
• We believe that the NanoViricides Platform technology meets this challenge of developing an escape-resistant drug.
• We believe that having developed the internal capabilities for cell culture testing of our ligands and nanoviricides against a variety of viruses has substantially strengthened and accelerated our drug development programs.

Industry Context

NanoViricides operates in the highly competitive and capital-intensive nano-biopharmaceutical sector, focusing on antiviral drugs. The company's host-mimicry platform addresses a critical unmet need for broad-spectrum antivirals that viruses cannot easily escape, a significant challenge highlighted by the COVID-19 pandemic and the emergence of drug-resistant influenza strains. The focus on orphan diseases like MPox, Smallpox, and Measles, alongside prevalent respiratory viruses like RSV and Influenza, aligns with global public health priorities and potential government funding opportunities. The market for effective antivirals, especially for emerging threats and diseases lacking approved treatments, is substantial, with RSV alone projected to reach $4.3 billion in three years and the smallpox/MPox market potentially in the billions. The company's in-house cGMP manufacturing capabilities are a notable advantage in an industry where manufacturing complex nanomedicines is a significant risk.

Comparison to Industry Standards

• NV-387's Phase I completion with no adverse events is a strong safety indicator, comparable to or exceeding the safety profiles of many early-stage drug candidates.
• In lethal lung infection animal models, oral NV-387 treatment for RSV led to full survival of mice, significantly outperforming ribavirin, which showed only a limited increase in lifespan. Ribavirin is a highly toxic last-resort drug for RSV.
• For Smallpox/MPox, oral NV-387 treatment in ectromelia virus-infected mice showed lifespan improvement comparable to tecovirimat (TPOXX, SIGA), an FDA Animal Rule-approved drug for Smallpox.
• In Influenza A/H3N2 lethal lung infection animal models, oral NV-387 substantially increased lifespan compared to approved drugs like oseltamivir (Tamiflu, Roche), peramivir (Rapivab, BioCryst), and baloxavir (Xofluza, Shionogi/Roche), which are known for viral escape issues.
• Unlike TPOXX, which failed in MPox clinical trials, and TEMBEXA (brincidofovir), which has significant black box warnings and adverse events (hepatic enzymes, DILI, embryo-fetal toxicity, male infertility), NV-387's strong safety profile in Phase I and animal models positions it as a potentially superior alternative for poxviruses.
• The company's claim of an 'escape-resistant' drug due to host-mimicry contrasts sharply with the known rapid emergence of resistance to drugs like Xofluza and Tamiflu in influenza viruses.

Management Changes

Corporate Governance

Legal Proceedings

• There are no pending legal proceedings against the company, and no action, suit, or proceeding has been threatened that is believed to have a material adverse effect on the business, financial position, results of operations, or liquidity.

Related Party Transactions

• TheraCour Pharma, Inc. (owned and controlled by Dr. Anil Diwan): Acquired property and equipment on behalf of the company for $6,250 during the period. Accounts payable to TheraCour were $663,776 as of September 30, 2025. Development fees and other costs charged by TheraCour were $539,522 for the three months ended September 30, 2025. License milestone payments are now contingent on the company having sufficient revenues.
• Karveer Meditech Private Limited (KMPL) (Dr. Anil Diwan is a passive investor and advisor): Accounts payable to KMPL were $237,367 as of September 30, 2025. The company reimburses KMPL for clinical trial expenses plus a 30% customary fee and receives 70% royalty on commercial sales in India.
• Dr. Anil Diwan (Chairman, President, CEO): Extended his employment agreement and was granted 10,204 shares of Series A preferred stock as compensation. Provided a standby Line of Credit to the company, increased to $3,000,000 and extended to March 31, 2027, bearing 12% interest, with no drawdowns as of September 30, 2025.

Stakeholder Impact

• Shareholders: Face dilution from recent and ongoing equity financings (ATM, registered direct offering, warrants). The 'going concern' warning indicates significant financial risk, but clinical progress and potential for non-dilutive funding offer long-term upside.
• Employees: Dr. Anil Diwan and Meeta Vyas had their employment agreements extended, providing stability in key leadership roles. Employee stock compensation (Series A preferred shares) aligns incentives.
• Customers (future): Potential for novel, broad-spectrum antiviral treatments for unmet medical needs (MPox, Smallpox, Measles, RSV, Influenza) could significantly benefit patients globally.
• Creditors: The $3 million line of credit from Dr. Anil Diwan provides a backstop, but the 'going concern' warning highlights inherent risks for all creditors.
• Regulatory Authorities: The company's engagement with US FDA for Orphan Drug Designations and Pre-IND applications, and approval for Phase II MPox trial in DRC, indicates active progress towards regulatory milestones.

Next Steps

• Finalize and submit the Phase Ia/Ib clinical study report (CSR) for NV-387 to regulatory authorities in India.
• Fulfill remaining conditions and provide final documentation for the Phase II MPox clinical trial in DRC.
• File a Clinical Trial Application (CTA) for a Phase II clinical trial of NV-387 as treatment for MPox.
• Execute the Phase II clinical trial for MPox and obtain top-line readout.
• Apply for Orphan Drug Designations (ODD) from the US FDA for NV-387 for Treatment of MPox, Smallpox, and Measles.
• File appropriate Pre-IND applications with the US FDA for NV-387 for MPox, Smallpox, and Measles.
• Seek a Pediatric Investigation Plan (PIP) Meeting with the US FDA for Measles and RSV indications.
• Initiate a Phase II clinical trial for evaluating NV-387 as a first-line, empiric therapy for any respiratory viral infection in India.
• Seek non-dilutive funding (grants and contracts) for advanced regulatory development of NV-387, especially for smallpox therapeutics, H5N1, COVID, Long COVID, and Measles.
• Pursue partnerships for all drug development programs, including COVID and Long COVID indications.
• Progress NV-HHV-1 into human clinical trials and further develop the HerpeCide program after NV-387 Phase II clinical trials.
• Continue to improve production processes and production scale at the cGMP-compliant manufacturing facility.
• Register the cGMP manufacturing facility with the FDA at the appropriate time.

Key Dates

Recommendation

NanoViricides presents a high-risk, high-reward profile. The 'going concern' warning and continued operating losses are significant concerns, typically warranting a 'sell' or 'strong sell' recommendation. However, the substantial progress in clinical development for NV-387, particularly the successful Phase I and the Phase II approval for MPox, coupled with the unique broad-spectrum, escape-resistant platform technology, offers considerable long-term potential. The recent capital raise, while dilutive, provides a lifeline for continued operations and clinical advancement. Given the early stage of drug development and the inherent uncertainties, a 'hold' recommendation is appropriate for investors with a high-risk tolerance who are willing to monitor the company's progress closely. The potential for non-dilutive government funding and partnerships for critical public health indications could be transformative, but these are not guaranteed. A 'buy' would be premature given the financial instability, and a 'sell' would ignore the significant scientific and clinical milestones achieved.

Keywords

Antiviral drugs, Nanomedicines, NV-387, MPox treatment, Smallpox treatment, Measles treatment, RSV treatment, Influenza treatment, Clinical trials, Biopharmaceutical, SEC filing, NNVC, Orphan Drug Designation, cGMP manufacturing, Capital raise, Going concern